These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34822220)

  • 1. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
    J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial.
    Wang R; Sun L; Wang X; Zhai Y; Wang L; Ma P; Wu C; Zhou Y; Chen R; Wang R; Zhang F; Hua W; Li A; Xia W; Gao Y; Li R; Lv S; Shao Y; Cao Y; Zhang T; Wu H; Cai C; Dai L
    Clin Infect Dis; 2024 Jul; 79(1):169-176. PubMed ID: 38236137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
    Ciccullo A; Baldin G; Borghi V; Oreni L; Lagi F; Fusco P; Giacomelli A; Torti C; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
    Int J Antimicrob Agents; 2024 Jan; 63(1):107040. PubMed ID: 37981074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
    HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
    Ambrosioni J; Rojas Liévano J; Berrocal L; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Ugarte A; Chivite I; Leal L; de Lazzari E; Miró JM; Blanco JL; Martinez E; Mallolas J
    J Antimicrob Chemother; 2022 Mar; 77(4):1133-1139. PubMed ID: 35040990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
    Mayer KH; Gelman M; Holmes J; Kraft J; Melbourne K; Mimiaga MJ
    J Acquir Immune Defic Syndr; 2022 May; 90(1):27-32. PubMed ID: 34991141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
    Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
    Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
    Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
    J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.
    Podany AT; Cramer Y; Imperial M; Rosenkranz SL; Avihingsanon A; Arduino R; Samaneka W; Gelmanova I; Savic R; Swindells S; Dawson R; Luetkemeyer AF
    Clin Infect Dis; 2024 Oct; 79(4):983-989. PubMed ID: 38568956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
    Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
    Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
    Chivite I; Berrocal L; de Lazzari E; Navadeh S; Lluis-Ganella C; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Blanco JL; Martínez E; Mallolas J; Ambrosioni J
    J Antimicrob Chemother; 2024 Aug; 79(8):1775-1783. PubMed ID: 38758191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
    Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
    J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide.
    Hsu JY; Sun HY; Chen LY; Chang SY; Chuang YC; Huang YS; Su YC; Liu WC; Hung CC
    J Glob Antimicrob Resist; 2024 Mar; 36():426-435. PubMed ID: 37923129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
    Gan L; Xie X; Fu Y; Song Y; Song C; Ren T; Long H
    Expert Rev Anti Infect Ther; 2024 Apr; 22(4):211-217. PubMed ID: 38058002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
    Corona D; Pérez-Valero I; Camacho A; Gutiérrez Liarte Á; Montero-Alonso M; Alemán MR; Ruiz-Seco P; Pérez González A; Riera M; Jarrin I; Rivero-Juárez A; Rivero A
    Int J Antimicrob Agents; 2024 Jan; 63(1):107016. PubMed ID: 37890734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV.
    Martín-Zaragoza L; Sánchez-Rubio-Ferrández J; Onteniente-González A; Gómez-Bermejo M; Rodríguez-Álvarez SJ; Monereo-Alonso A; Molina-García T
    Farm Hosp; 2024; 48(4):T171-T175. PubMed ID: 38806363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.